Clinical significance of aberrant DEUP1 promoter methylation in hepatocellular carcinoma

Yu,Qiwen; Cao,Shengli; Tang,Hongwei; Li,Jie; Guo,Wenzhi; Zhang,Shuijun

doi:10.3892/ol.2019.10421

Clinical significance of aberrant DEUP1 promoter methylation in hepatocellular carcinoma

Authors:
- Qiwen Yu
- Shengli Cao
- Hongwei Tang
- Jie Li
- Wenzhi Guo
- Shuijun Zhang
View Affiliations

Affiliations: Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China, Key Laboratory of Hepatobiliary and Pancreatic Surgery and Digestive Organ Transplantation of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China
Published online on: May 30, 2019 https://doi.org/10.3892/ol.2019.10421
Pages: 1356-1364
Copyright: © Yu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Accumulating studies have shown that methylation of tumor suppressor genes plays an important role in tumorigenesis. Deuterosome assembly protein 1 (DEUP1) has been implicated as a suppressor gene in some tumors and promoter methylation led to silencing of its expression. However, the roles of DEUP1 promoter methylation and expression in hepatocellular carcinoma (HCC) are not clear. In the present study, the expression and methylation of the DEUP1 promoter in HCC was investigated and the correlations with HCC occurrence and development were explored. A total of 60 HCC tumor and adjacent non‑tumor tissues were included in this study. Reverse transcription‑polymerase chain reaction, bisulfite PCR sequencing, immunohistochemistry and western blotting were applied to detect the methylation status of the DEUP1 promoter and its expression, and to analyze their associations with clinicopathological data. The results showed that the mRNA and protein expression of DEUP1 in adjacent non‑tumor tissues was significantly increased compared with in the HCC tissues. DEUP1 promoter methylation was detected in 46/60 (76.7%) tumor tissues and there was a negative correlation between promoter methylation and DEUP1 protein expression (P<0.05). Analysis of the clinicopathological data revealed that the mRNA and protein expression of DEUP1, and its promoter methylation status, was associated with tumor node metastasis stage and tumor differentiation. Taken together, the results of the present study suggested that methylation of the DEUP1 promoter maybe an important mechanism for gene inactivation and has a critical role in the occurrence and development of liver cancer.

View Figures

View References

1	Na TY, Ka NL, Rhee H, Kyeong D, Kim MH, Seong JK, Park YN and Lee MO: Interaction of hepatitis B virus X protein with PARP1 results in inhibition of DNA repair in hepatocellular carcinoma. Oncogene. 35:5435–5445. 2016. View Article : Google Scholar : PubMed/NCBI
2	Branda M and Wands JR: Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma. Hepatology. 43:891–902. 2006. View Article : Google Scholar : PubMed/NCBI
3	Wahid B, Ali A, Rafique S and Idrees M: New insights into the epigenetics of hepatocellular carcinoma. Biomed Res Int. 2017:16095752017. View Article : Google Scholar : PubMed/NCBI
4	Zhang X, Cheng Q, Yin H and Yang G: Regulation of autophagy and EMT by the interplay between p53 and RAS during cancer progression (Review). Int J Oncol. 51:18–24. 2017. View Article : Google Scholar : PubMed/NCBI
5	Appleton K, Mackay HJ, Judson I, Plumb JA, McCormick C, Strathdee G, Lee C, Barrett S, Reade S, Jadayel D, et al: Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol. 25:4603–4609. 2007. View Article : Google Scholar : PubMed/NCBI
6	Amato RJ: Inhibition of DNA methylation by antisense oligonucleotide MG98 as cancer therapy. Clin Genitourin Cancer. 5:422–426. 2007. View Article : Google Scholar : PubMed/NCBI
7	Wang Y, Zhang J, Xiao X, Liu H, Wang F, Li S, Wen Y, Wei Y, Su J and Zhang Y: The identification of age-associated cancer markers by an integrative analysis of dynamic DNA methylation changes. Sci Rep. 6:227222016. View Article : Google Scholar : PubMed/NCBI
8	Pfeifer GP: Defining driver DNA methylation changes in human cancer. Int J Mol Sci. 19:E11662018. View Article : Google Scholar : PubMed/NCBI
9	Chen Y, Luo D, Tian W, Li Z and Zhang X: Demethylation of miR-495 inhibits cell proliferation, migration and promotes apoptosis by targeting STAT-3 in breast cancer. Oncol Rep. 37:3581–3589. 2017. View Article : Google Scholar : PubMed/NCBI
10	Yin DT, Xu J, Lei M, Li H, Wang Y, Liu Z, Zhou Y and Xing M: Characterization of the novel tumor-suppressor gene CCDC67 in papillary thyroid carcinoma. Oncotarget. 7:5830–5841. 2016.PubMed/NCBI
11	Park SJ, Jang HR, Kim M, Kim JH, Kwon OH, Park JL, Noh SM, Song KS, Kim SY, Kim YH and Kim YS: Epigenetic alteration of CCDC67 and its tumor suppressor function in gastric cancer. Carcinogenesis. 33:1494–1501. 2012. View Article : Google Scholar : PubMed/NCBI
12	Kamarajah SK, Frankel TL, Sonnenday C, Cho CS and Nathan H: Critical evaluation of the american joint commission on cancer (AJCC) 8th edition staging system for patients with hepatocellular carcinoma (HCC): A Surveillance, Epidemiology, End Results (SEER) analysis. J Surg Oncol. 117:644–650. 2018. View Article : Google Scholar : PubMed/NCBI
13	Böck J, Appenzeller S, Haertle L, Schneider T, Gehrig A, Schröder J, Rost S, Wolf B, Bartram CR, Sutter C and Haaf T: Single CpG hypermethylation, allele methylation errors, and decreased expression of multiple tumor suppressor genes in normal body cells of mutation-negative early-onset and high-risk breast cancer patients. Int J Cancer. 143:1416–1425. 2018. View Article : Google Scholar : PubMed/NCBI
14	Murphy GA, Spedale EJ, Powell ST, Pillus L, Schultz SC and Chen L: The Sir4 C-terminal coiled coil is required for telomeric and mating type silencing in saccharomyces cerevisiae. J Mol Biol. 334:769–780. 2003. View Article : Google Scholar : PubMed/NCBI
15	Tamaki H, Sanda M, Katsumata O, Hara Y, Fukaya M and Sakagami H: Pilt is a coiled-coil domain-containing protein that localizes at the trans-Golgi complex and regulates its structure. FEBS Lett. 586:3064–3070. 2012. View Article : Google Scholar : PubMed/NCBI
16	Burkhard P, Stetefeld J and Strelkov SV: Coiled coils: A highly versatile protein folding motif. Trends Cell Biol. 11:82–88. 2001. View Article : Google Scholar : PubMed/NCBI
17	Zeng JD, Zhang N, Zhao GJ, Xu LX, Yang Y, Xu XY, Chen MK, Wang HY, Zheng SX and Li XX: MT1G is silenced by DNA methylation and contributes to the pathogenesis of hepatocellular carcinoma. J Cancer. 9:2807–2816. 2018. View Article : Google Scholar : PubMed/NCBI
18	Kishino T, Niwa T, Yamashita S, Takahashi T, Nakazato H, Nakajima T, Igaki H, Tachimori Y, Suzuki Y and Ushijima T: Integrated analysis of DNA methylation and mutations in esophageal squamous cell carcinoma. Mol Carcinog. 55:2077–2088. 2016. View Article : Google Scholar : PubMed/NCBI
19	Kwon H, Song K, Han C, Zhang J, Lu L, Chen W and Wu T: Epigenetic silencing of miRNA-34a in human cholangiocarcinoma via EZH2 and DNA methylation Impact on Regulation of Notch Pathway. Am J Pathol. 187:2288–2299. 2017. View Article : Google Scholar : PubMed/NCBI
20	Alipour M, Zargar SJ, Safarian S, Fouladdel S, Azizi E and Jafargholizadeh N: The study of DNA methylation of bax gene promoter in breast and colorectal carcinoma cell lines. Iran J Cancer Prev. 6:59–64. 2013.PubMed/NCBI
21	Lu Y, Zabihula B, Yibulayin W and Liu X: Methylation and expression of RECK, P53 and RUNX genes in patients with esophageal cancer. Oncol Lett. 14:5293–5298. 2017.PubMed/NCBI
22	Zheng J, Mei Y, Xiang P, Zhai G, Zhao N, Xu C, Liu M, Pan Z, Tang K and Jia D: DNA methylation affects metastasis of renal cancer and is associated with TGF-β/RUNX3 inhibition. Cancer Cell Int. 18:562018. View Article : Google Scholar : PubMed/NCBI
23	Song L, Yu H and Li Y: Diagnosis of lung cancer by SHOX2 gene methylation assay. Mol Diagn Ther. 19:159–167. 2015. View Article : Google Scholar : PubMed/NCBI
24	Sajadian SO, Ehnert S, Vakilian H, Koutsouraki E, Damm G, Seehofer D, Thasler W, Dooley S, Baharvand H, Sipos B and Nussler AK: Induction of active demethylation and 5hmC formation by 5-azacytidine is TET2 dependent and suggests new treatment strategies against hepatocellular carcinoma. Clin Epigenetics. 7:982015. View Article : Google Scholar : PubMed/NCBI
25	Zahnow CA, Topper M, Stone M, Murray-Stewart T, Li H, Baylin SB and Casero RA Jr: Inhibitors of DNA methylation, histone deacetylation, and histone demethylation: A perfect combination for cancer therapy. Adv Cancer Res. 130:55–111. 2016. View Article : Google Scholar : PubMed/NCBI